Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells.

@article{Janzer2014MetforminAP,
  title={Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells.},
  author={Andreas Janzer and Natalie J. German and Karina N Gonzalez-Herrera and John M. Asara and Marcia C Haigis and Kevin Struhl},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2014},
  volume={111 29},
  pages={10574-9}
}
Metformin, a first-line diabetes drug linked to cancer prevention in retrospective clinical analyses, inhibits cellular transformation and selectively kills breast cancer stem cells (CSCs). Although a few metabolic effects of metformin and the related biguanide phenformin have been investigated in established cancer cell lines, the global metabolic impact of biguanides during the process of neoplastic transformation and in CSCs is unknown. Here, we use LC/MS/MS metabolomics (>200 metabolites… CONTINUE READING